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Key Concepts • The highest human exposures to polychlorinated 
biphenyls (PCBs) occur via the consumption of 
contaminated fish and, in certain occupational 
settings, via contact with equipment or materials 
made before 1977. 
• Recent studies indicate that maternal consumption 
of PCB-contaminated fish can cause disturbances in 
reproductive parameters and neurobehavioral and 
developmental deficits in newborns and older 
children. 
• Evidence shows that exposures to high 
concentrations of PCBs cause adverse dermal 
effects in humans. On the basis of sufficient 
evidence of carcinogenicity in humans and 
experimental animals, the International Agency for 
Research on Cancer (IARC) classified PCBs as 
carcinogenic to humans (Group 1).  
About This and 
Other Case Studies 
in Environmental 
Medicine  
This educational case study document is one in a 
series of self-instructional modules designed to 
increase the primary care provider’s knowledge of 
hazardous substances in the environment and to 
promote the adoption of medical practices that aid 
in the evaluation and care of potentially exposed 
patients. The complete series of Case Studies in 
Environmental Medicine is located on the ATSDR 
Web site at 
URL: http://www.atsdr.cdc.gov/csem/csem.html In 
addition, the downloadable PDF version of this 
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educational series and other environmental 
medicine materials provides content in an 
electronic, printable format, especially for those 
who may lack adequate Internet service. 
 
Acknowledgements We gratefully acknowledge the work of the 
medical writers, editors, and reviewers in 
producing this educational resource.  
Contributors to this version of the Case Study 
in Environmental Medicine are listed below. 
Please Note: Each content expert for this case 
study has indicated that there is no conflict of 
interest that would bias the case study 
content. 
CDC/ATSDR Author(s): Dianyi Yu, MD 
CDC/ATSDR Planners: Charlton Coles, PhD; John 
Doyle, MPA; Kimberly Gehle, MD; Sharon L. Hall, 
PhD; Michael Hatcher, DrPH; Barbara M. Riley, RN; 
Delene Roberts, MSA; Brian Tencza, MS; Dianyi Yu, 
MD. 
Peer Reviewers: Obaid Faroon, DVM, PhD; John 
Osterich, PhD; Avima M. Ruder, Ph.D.; Anne 
Sowell, PhD; Mohammed Uddin, MD, MPH. 









Visit http://www.atsdr.cdc.gov/csem/conteduc.html for 
more information about continuing medical education 
credits, continuing nursing education credits, and other 
continuing education units. Access the Assessment and 
Posttest by 
selecting http://www2a.cdc.gov/TCEOnline/registration/d












The Centers for Disease Control and Prevention (CDC) is 
accredited by the Accreditation Council for Continuing 
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units (CEU) for CPH recertification credits from 
CDC.  Please select CEU as your choice for continuing 
education when registering for a course on TCEOnline. 
Learners seeking CPH should use the guidelines provided 
by the NBPHE for calculating recertification credits.  For 









The state of knowledge regarding the treatment of patients 
potentially exposed to hazardous substances in the 
environment is constantly evolving and is often uncertain. 
In developing its educational products, ATSDR has made a 
diligent effort to ensure the accuracy and the currency of 
the presented information. ATSDR, however, makes no 
claim that the environmental medicine and health 
education resources discussed in these products 
comprehensively address all possible situations related to 
various substances. The products are intended for 
educational use to build the knowledge of physicians and 
other health professionals in assessing the conditions and 
managing the treatment of patients potentially exposed to 
hazardous substances. The products are not a substitute 
for a health-care provider's professional judgment. Please 
interpret the environmental medicine and the health 
education resources in light of specific information 
regarding the patient and in conjunction with other medical 
authorities. 
Use of trade names in ATSDR products is for identification 
purposes only and does not imply endorsement by the 
Agency for Toxic Substances and Disease Registry or the 
U.S. Department of Health and Human Services. 
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Introduction The goal of ATSDR’s CSEM is to increase the primary 
health care provider’s knowledge of hazardous 
substances in the environment and to help evaluate and 
treat potentially exposed patients. This CSEM focuses on 
PCB toxicity. 
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Availability Two versions of the PCB toxicity CSEM are available. 
• The HTML versionhttp://atsdr-
link.cdc.gov/csem/csem.asp?csem=30&po=0 
provides content through the Internet. This version 
offers interactive exercises and prescriptive 
feedback to the user. 
• The downloadable PDF version 
http://www.atsdr.cdc.gov/csem/pcb/docs/pcb.pdf 
provides content in an electronic, printable format. 
Instructions To make the most effective use of this course: 
• Take the Initial Check to assess your current 
knowledge about PCB toxicity. 
• Read the title, learning objectives, text, and key 
points in each section. 
• Complete the progress check exercises at the end 
of each section and check your answers. 
• Complete and submit your assessment and posttest 
response online if you wish to obtain free 
continuing education credit. You can print your 




This course is designed to help you learn efficiently. 
Topics are clearly labeled so that you can skip or quickly 
scan sections with which you are already familiar. This 
labeling will also allow you to use this training material 
as a handy reference. To help you identify and absorb 
important content quickly, each section is structured in 




Title Serves as a focus question that you should be able to 
answer after completing the section 
Learning 
Objectives 
Describes specific content addressed in each section and 
focuses your attention on important points 
Text Provides the information you need to answer the focus 
questions and achieve the learning objectives 
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Key Points Highlights important issues and helps you review 
Progress Check 
Exercises 
Enables you to test yourself to determine whether you 
have mastered the learning objectives 
Progress Check 
Answers 
Provides feedback to ensure you understand the content 




Upon completion of the PCBs toxicity CSEM, you will be 
able to meet the objectives as outlined.  
Content Area Objectives 
Overview • Describe key characteristics of PCBs 
Exposure 
Pathways 
• Identify sources of exposure to PCBs 
• Identify routes of exposure to PCBs 
Who is at Risk • Identify who is at risk for exposure to PCBs 
Standards and 
Regulations 
• Identify EPA’s maximum contaminant level (MCL) 
for PCBs in drinking water  
• Identify FDA’s tolerance levels for PCBs in food 
Biological Fate • Describe characteristics of the metabolism of PCBs 
in the body 
Health Effects • Describe adverse health effects associated with 
exposure to PCBs 
Clinical 
Assessment 
• Describe characteristic findings on clinical 
assessment of patients exposed to PCBs  
• Describe a rational approach for evaluating a 
patient with a history of occupational and/or 
environmental exposure to PCBs 
• Describe measurements that can help diagnose  
exposure to PCBs 
Treatment and 
Management 
• Describe the principal treatment strategy for 
managing PCB poisoning 
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• Describe the measures for preventing occupational 




• Describe instructions appropriate for patients 
exposed to PCBs 
Initial Check 
Instructions This Initial Check will help you assess your current 
knowledge about PCB toxicity. To take the Initial Check, 




A 48-year-old handyman has progressive cystic 
acne and abnormal liver function. 
A 48-year-old man that you are treating for acne 
vulgaris returns to your clinic for a follow-up 
appointment. You first saw this patient about 3 weeks 
ago. At that time, he had multiple acneiform lesions in 
the malar and periorbital areas. Both cystic and 
comedonal lesions were present; most ranged between 
3 and 6 millimeters (mm) in diameter, and some were 
edematous. The patient noted that he was surprised 
about the development of acne at his age; he never 
suffered from this condition during adolescence. He had 
used over-the-counter astringents and anti-acne 
medications, but they had not affected the lesions. 
A review of the patient’s medical history indicates that 
he has  
• No history of hepatitis,  
• No recollection of contact with hepatitis patients,  
• No evidence of liver difficulties, and  
• No record of blood transfusion.  
The patient has no family history of cardiovascular 
disease or cancer. The patient does not smoke; he 
drinks two to three bottles of beer each evening and 
sometimes more on weekends. He is taking no 
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medications other than over-the-counter dermatologic 
medications. 
The patient is married and has three teenaged children. 
His wife and children are in good health. They live in a 
high-rise apartment building where the patient has been 
a handyman and part-time building manager for the 
past year. He spends a lot of time in the basement area, 
which includes   
• Heating facilities, 
• A laundry,  
• A recreation room with pool table, and 
• A workshop. 
The patient is an avid fisherman who spends most 
weekends fishing and eating his catch with his two sons.  
At the end of the patient’s initial visit, you prescribed a 
topical antibiotic and instructed the patient on its use. 
After reassuring the patient that stronger prescription 
medications are available to treat acne, you ordered a 
serum biochemical and hematologic profile to document 
baseline values. 
During today’s physical examination, you note little or 
no improvement in the patient’s acne. The ratio of cystic 
to comedonal lesions appears to have increased, and 
many lesions appear to have become more edematous 
and erythematous. The patient has several new 
comedones on his chin, and he points out what appears 
to be developing areas of folliculitis on his chest and 
forearms. 
In addition to this worsening of the patient’s acne, your 
physical examination of the patient reveals mild, non-
tender hepatomegaly without jaundice. This finding 
causes you to review the results of the biochemical 
panel. You note the following abnormalities: 
• Total bilirubin 2.8 milligrams per deciliter (mg/dL) 
(normal 0–1.5), 
• Direct bilirubin 0.4 mg/dL (normal 0–0.4), 
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• Serum glutamic-pyruvic transaminase (SGPT) 
(alanine aminotransferase [ALT]) 74 international 
units per liter (IU/L) (normal 0–50), 
• Serum glutamic-oxaloacetic transaminase (SGOT) 
(aspartate aminotransferase [AST]) 88 IU/L 
(normal 0–50), 
• Glutamyl transpeptidase (GGTP or GGT) 190 IU/L 
(normal 15–85), and 
• Lactate dehydrogenase (LDH) 230 IU/L (normal 
50–225). 
The results of all other tests, including the complete 
blood count, alkaline phosphatase (ALP), blood urea 





1. What should be included in the patient’s problem 
list? 
2. What is a differential diagnosis for the patient’s 
altered liver enzymes? 
3. What tests would help you arrive at a diagnosis? 
4. You persistently pose detailed questions to the 
patient regarding his work, hobbies, recreational 
activities, and possible contact with hepatotoxins.  
 The patient reveals that he frequently wipes up a 
“dark, oily discharge” near a large electrical 
transformer in the work area in the basement 
workshop. The discharge has produced a gummy 
residue on tools and other surfaces. He mentions 
he sometimes feels dizzy and nauseated after 
working in the basement all day. 
Is this additional information related to the clinical 
findings? 
5. Is there a need to be concerned about exposure to 
PCBs when the clinical effects in this patient seem 
so limited?  
6. Are other sources of PCB exposure likely for this 
patient? 
7. What confirming laboratory test can be conducted 
to establish the diagnosis of PCB exposure? 
8. The doctor requests a serum PCB analysis. The 
laboratory reports a level of 125 parts per billion 
(ppb), with no normal range indicated. How will 
you interpret this report? 
9. What steps should be recommended to patients 
when PCB-related health effects are suspected? 
10. What additional steps should be taken for the 





1. The patient’s problem list includes acne vulgaris, 
which is atypical because of the location of the 
lesions and their late onset with no history of 
outbreaks during adolescence. The mildly altered 
liver functions are nonspecific but clinically 
unexpected.  
More information for this answer can be found in 
the “Clinical Assessment – Signs and Symptoms” 
section. 
2. The combination of asymptomatic hepatomegaly 
and mild nonspecific elevations of hepatic enzymes 
suggests a chronic inflammatory liver process or 
hepatitis. Hepatitis can be drug-induced, toxic, 
infectious, genetic, or caused by connective tissue 
disease. 
The major cause of liver disease in the United 
States is ethanol ingestion. Less commonly, 
environmental exposures cause either acute or 
chronic toxic hepatitis. Some connective tissue 
diseases such as lupus erythematosus are 
associated with a specific type of hepatitis. 
Infectious hepatitis includes those attributed to the 
viruses such as A, B, C, and other possible agents 
of non-A, non-B hepatitis. Hepatitis can also occur 
with Epstein-Barr virus and cytomegalovirus 
infections. Infiltrative diseases such as sarcoidosis 
or amyloidosis, and rare genetic diseases such as 
Wilson disease, primary hemochromatosis, and 
alpha-1-antitrypsin deficiency should be excluded 
as causes of hepatitis also. 
More information for this answer can be found in 
the “Clinical Assessment – Laboratory Tests” 
section. 
3. Repeat ALT, AST, GGT, and bilirubin testing; test 
ALP and prothrombin time; and test for hepatitis 
viral serologies, heterophil antibody (anti-EBV 
capsid IgM), anti-nuclear antibody, anti-smooth 
muscle antibody, and anti-mitochondrial antibody. 
Consider hemachromatosis (serum ferritin, iron, 
 15 
and iron binding capacity), Wilson disease (serum 
copper and ceruloplasmin), and parasitic hepatitis 
as possible causes of chronic hepatitis.  
 Assays for suspected hepatotoxins and biopsy of 
adipose tissue might also be of value. Further 
evaluation might include ultrasound and 
percutaneous liver biopsy if other tests do not 
provide sufficient information. 
More information for this answer can be found in 
the “Clinical Assessment – Laboratory Tests” 
section. 
4. Older electrical transformers and capacitors can 
contain PCBs as a dielectric and heat-transfer fluid. 
Leaks in this equipment could allow PCBs to 
volatilize under conditions of increased 
temperature. A person with chronic exposure to the 
vapors or residue could eventually receive a 
significant PCB dose through both dermal and 
inhalation routes. 
More information for this answer can be found in 
the “How Are People Exposed to PCBs?” section. 
5. Notably, potential carcinogenicity is the main 
reason PCB production was banned in the United 
States. EPA has determined that PCBs are probable 
human carcinogens and has assigned them the 
cancer weight-of-evidence classification B2. DHHS 
concluded that PCBs are reasonably anticipated to 
be carcinogenic in humans, based on sufficient 
evidence of carcinogenicity in animals. In February 
2013, 26 experts from 12 countries met at the 
International Agency for Research on Cancer 
(IARC), Lyon, France, to reassess the 
carcinogenicity of polychlorinated biphenyls (PCBs). 
On the basis of sufficient evidence of 
carcinogenicity in humans and experimental 
animals, the IARC classified PCBs as carcinogenic 
to humans (Group 1). The classification is based on 
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consistent association between PCB exposure and 
increased risk of melanoma in humans. 
More information for this answer can be found in 
the “What Are the Physiologic Effects of PCBs?” 
section. 
6. In addition to possible dermal and inhalation 
exposure, the patient might be exposed by 
consuming contaminated fish, a potential source of 
PCBs. 
More information for this answer can be found in 
the “How Are People Exposed to PCBs?” section. 
7. Select laboratories have the capability to perform 
PCB analyses on human tissue. The lipophilic 
nature of PCBs causes them to accumulate in fat; 
consequently, analysis of adipose tissue obtained 
by biopsy has been advocated as a measure of 
long-term exposure. Serum PCB analysis, which is 
less invasive than fat biopsy, is readily available. 
Health risks are not consistent necessarily with PCB 
levels, but a serum measurement is useful for 
gauging the patient’s exposure. 
More information for this answer can be found in 
the “Clinical Assessment – Laboratory Tests” 
section. 
8. A correlation between increasing levels of serum 
PCBs and dermatologic findings, including 
chloracne, has not been found consistently in 
human epidemiologic studies. However, statistically 
significant associations between dermatologic 
effects and plasma levels of higher chlorinated PCB 
congeners have been reported.  
PCB compounds generally can be found at the parts 
per trillion (ppt) levels in the lipid stores of 
humans, especially persons living in an 
industrialized society. The general population is 
exposed to PCB compounds primarily through the 
ingestion of high-fat foods such as dairy products, 
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eggs, animal fats, and some fish and wildlife [CDC 
2009b; Hopf et al. 2009; Patterson et al. 2008]. By 
comparison, the case study patient’s PCB serum 
level of 125 ppb is consistent with PCB exposure as 
a cause for his unusual acne, and PCB exposure 
might be contributing to the hepatic effects noted. 
More information for this answer can be found in 
the “Clinical Assessment – Laboratory Tests” 
section. 
9. The first objective should be to stop the exposure. 
In this case, the patient should stay away from the 
basement until the transformer is repaired and the 
basement area is cleaned by a professional familiar 
with PCB removal. He should also check with his 
state advisory on PCB-fish contamination and not 
eat fish from contaminated areas until his PCB level 
normalizes and the fish are declared 
uncontaminated. Many states issue advisories on 
fish consumption based on where the fish are 
caught. Fish advisories also provide guidance on 
how to choose fish that are safer to eat and on 
safer ways to prepare and cook fish. Avoiding 
exposure is especially important because no 
specific treatment exists for PCB accumulation. The 
need to avoid other hepatotoxic substances, 
including ethanol, should be stressed. Confirmation 
of exposure with a serum PCB level should be 
obtained. 
More information for this answer can be found in 
the “How Should Patients Exposed to PCBs Be 
Treated and Managed?” section. 
10. Because stopping exposure is of prime importance, 
the physician can be most helpful by advising the 
patient that proper abatement by professionals is 
necessary. In this case, the owner of the building 
should be notified of the potential health hazard 
and should contact the local public health agency. 
This might require the assistance of local, state, or 
federal agencies such as the department of public 
health and EPA. These agencies can cooperate with 
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entities involved to ensure remediation of the 
harmful exposure. It is important to prevent other 
persons from using the basement areas until 
cleanup is complete. In addition, the patient should 
be informed of the availability of fishing and game 
advisories particular to his state, and he should be 
encouraged to observe the recommendations of 
these advisories. 
More information for this answer can be found in 
the “How Should Patients Exposed to PCBs Be 
Treated and Managed?” section. 
What Are Polychlorinated Biphenyls (PCBs)? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• Describe key characteristics of PCBs. 
Definition PCBs are chemicals formed by attaching one or more 
chlorine atoms (at the Xs in Figure 1 below) to a pair of 
connected benzene rings. 
 
Figure 1: Polychlorinated Biphenyls (PCBs) 
Depending on the number and position of chlorine atoms 
attached to the biphenyl ring structure, 209 different 
PCB congeners can be formed. PCB congeners can be 
divided into the coplanar, the mono-ortho-substituted 
PCBs, and other non-dioxin-like PCBs. The significance 
of this designation is that coplanar and some of the 








The chlorination pattern of the PCBs determines the 
toxicity of the substance. A number of PCB congeners 
show dioxin-like toxicity. These PCBs have no more 
than one chlorine atom at the ortho-position 
(polychlorinated non-ortho and mono-ortho biphenyls). 
The phenyl rings of these molecules can rotate and 
adopt a coplanar structure, which leads to the same 
toxicity as the polychlorinated dibenzo-p-dioxins 
(PCDDs) and polychlorinated dibenzofurans (PCDFs). 
The toxic effects of these dioxin-like PCBs are discussed 
in detail in later sections of this document. 
A number of PCB congeners, however, have two or more 
of the ortho-positions in the biphenyl molecules 
occupied by chlorine molecules. For these, the two 
phenyl rings are not in the same plane, and these PCBs 
express non-dioxin-like toxicity.  
Commercial PCB products are mixtures of different PCB 
congeners and contain small amounts of PCDFs or 
PCDDs. Contamination is a concern because the toxicity 
of these contaminants is generally much greater than 
that of PCBs [ATSDR 2000]. 
Uses 
 
Because of their insulating and nonflammable 
properties, PCBs were marketed for nearly 50 years 
between 1929 and 1977. They were used in making 
• Diffusion pump oils, 
• Extenders for pesticides, 
• Heat exchange and dielectric fluids in transformers 
and capacitors, 
• Hydraulic and lubricating fluids, and 
• As ingredients in caulking compounds, paints, 
adhesives, flame retardants, and plasticizers. 
In 1977, the United States banned production of PCBs 
because of their potential carcinogenicity. 













Key Points • PCBs are manufactured chemicals that were 
produced for nearly 50 years in the United States 
before they were banned in 1977. 




1. Select the best answer from the following choices: 
A. Commercial PCB products are mixtures of 
different PCB congeners. 
B. Commercial PCB products commonly are 
contaminated with small amounts of 
polychlorinated dibenzofurans (furans) or 
polychlorinated dibenzodioxins (dioxins). 
C. PCB manufacturing was banned in the United 
States in 1977. 
D. All of the above. 
To review relevant content, see “Chemical 
Properties and Uses” in this section. 
Where Are PCBs Found? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• Identify sources of exposure to PCBs. 
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Introduction No known natural sources of PCBs exist. The United 
States banned production of these chemicals in 1977, 
when their ability to accumulate in the environment and 
to cause harmful effects became apparent [ATSDR 
2000]. Today, the major source of exposure to ambient 
PCBs is environmental cycling of PCBs previously 




Between 1929 and 1977, more than 1.25 billion pounds 
of PCBs were produced in the United States [ATSDR 
2000]. PCBs can be released into the general 
environment by or from 
• Disposal of PCB-containing consumer products in 
municipal landfills 
• Illegal or improper dumping of waste that 
contained PCBs, such as transformer fluids 
• Leaks (fugitive emissions) from electrical 
transformers and capacitors containing PCBs 
• Poorly maintained toxic waste sites 
Once released into the environment, PCBs 
• bioaccumulate and biomagnify as they move up the 
food chain, 
• degrade relatively slowly, and 
• are cycled and transported within the ecosystem 
[ATSDR 2000; Safe 2007]. 
PCBs have been identified in at least 500 of the 1,598 
hazardous waste sites on the EPA’s National Priorities 
List, and low levels of PCBs can be found throughout the 





Once released into the environment, PCBs adsorb 
strongly to soil and sediment. As a result, these 
compounds tend to persist in the environment, with 
half-lives for most congeners ranging from months to 
years. PCBs leach from soil slowly, particularly the more 
highly chlorinated congeners, and translocate to plants 
via soil insignificantly. 
Cycling of PCBs through the environment involves 
volatilization from land and water surfaces into the 
atmosphere, with subsequent removal from the 
atmosphere by wet or dry deposition, then 
revolatilization. In the general population, inhalation of 
these airborne PCBs is one route of exposure, in addition 
to the food source of exposure to PCBs. 
Key Points • Environmental contamination from PCBs has been 
caused by accidental releases, careless disposal 
practices, and leaks from industrial facilities or 
chemical waste-water disposal sites. 
• PCBs degrade very slowly, are cycled and 
transported within the ecosystem, and 




2. Once released into the environment, PCBs may 
undergo all of the following EXCEPT 
A. Volatilization from land and water surfaces into 
the atmosphere 
B. Biotransformation into more complex undefined 
mixtures 
C. Fast degradation within the ecosystem 
D. Strong adsorption to soil and sediment 
To review relevant content, see “Released into 
Environment” in this section. 
What Are Routes of Exposure for PCBs? 
Learning 
Objective 
Upon completion of this section, you will be able to 
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• Identify routes of exposure to PCBs. 
Introduction Although PCBs are no longer manufactured in the 
United States, people can still be exposed to them. The 
two main sources of exposure to PCBs are the 
environment and the workplace.  
Because they are resistant to degradation, highly 
chlorinated PCB compounds can persist in the 
environment for decades. However, over the past two 
decades, concentrations of PCBs in most environmental 







Food is the main source of exposure to PCBs for the 
general population (CDC 2009b). Exposure occurs 
primarily by ingesting high-fat foods—such as dairy 
products, eggs, and animal fats—and some fish and 
wildlife [ATSDR 2000; CDC 2009b; Fisher 1999; 
Gunderson and Gunderson 1988; Hopf et al. 2009; 
Patterson et al. 2008]. 
CDC publishes the National Report on Human Exposure 
to Environmental Chemicals. This report is an ongoing 
assessment of the exposure to environmental chemicals 
in the general U.S. population. The Fourth Report (CDC 
2009b) contains data for years 1999–2000, 2001–
2002, and 2003–2004 from participants in National 
Health and Nutrition Examination Survey (NHANES). 
Detailed information on NHANES is available 
at http://www.cdc.gov/nchs/nhanes/about_nhanes.htm
.  
Serum concentrations of PCBs were found to reflect 
cumulative past exposure in the general U.S. population 








In aquatic environments, the high lipophilicity of PCBs 
causes these compounds to partition out of the water 
and become adsorbed preferentially to sediments. 
Although sediment adsorption helps prevent the 
contamination of drinking-water supplies, the 
partitioning of PCBs to sediments plays a role in the 
tendency of these compounds to become concentrated 
in aquatic organisms. Bottom-feeding fish ingest and 
accumulate PCBs from sediment. The resistance of 
these compounds to biodegradation causes PCBs to 
become more concentrated as they move upward 
through the food chain from the bottom-feeding 
organisms. As a result of this bioconcentration and 
biomagnification, PCB levels in aquatic organisms can 
be as much as one million times higher than the levels 
in the aquatic environment [ATSDR 2000]. 
In the National Study of Chemical Residues in Fish 
conducted between 1986 and 1989 [EPA 1992a, 
1992b], the mean concentration of PCBs in bottom-
feeding and game fish was 1.9 parts per million (ppm). 
However, PCB levels as high as 20 ppm have been 
detected in game fish taken from waters near 




The U.S. Food and Drug Administration (FDA)’s Total 
Diet Studies have revealed that total PCB levels have 
shown a downward trend in concentration from the 
middle 1970s to the middle 1980s and a relatively 
steady intake from 1982 to 1997. For example, total 
diet studies conducted from 1982 to 1984 for adults 
between the ages of 25 and 30 indicated that the mean 
daily intake of PCBs was <0.001 micrograms/kilograms 
(μg/kg) body weight/day while in the 1997 study, the 







People living near incinerators, other PCB-disposal 
facilities, or NPL hazardous waste sites where PCBs 
have been detected may receive higher PCB exposures 
than the general population. These exposures may be 
through ingestion, inhalation, or skin contact [ATSDR 
2000]. 
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Do-it-yourselfers repairing or removing older 
construction materials, including plaster, paint, and 




and Dermal  
Occupational exposure to PCBs occurs mainly via the 
inhalation and dermal routes. 
Commercial PCB mixtures vary from colorless to dark 
brown oils, and from viscous liquids to sticky resinous 
semisolids. Although PCBs evaporate slowly at room 
temperature, the volatility of PCBs increases 
dramatically with even a small rise in temperature. 
Equipment that contains PCBs can overheat and 
vaporize significant quantities of these compounds, 
creating an inhalation hazard that can be magnified by 
poor ventilation. 
Because of their highly lipophilic nature, PCBs also can 
be absorbed through the skin following contact with 
contaminated equipment, water, or soil. 
Products that contain PCBs are no longer manufactured, 
thus occupational exposure no longer occurs in those 
settings. However, it might occur  
• During the maintenance or repair of old equipment 
that contains PCBs,  
• As a result of accidents involving such equipment 
[Schecter AJ and Charles 1991; Wolff 1985], or 
• During waste-site cleanup or disposal activities 
[ATSDR 2000; Luotamo et al. 1993; Schecter A et 
al. 1994]. 
• During repair or removal of older construction 
materials, including plaster, paint, and caulk that 
contain PCBs. 
Today, PCBs are found mainly in transformers and 
capacitors manufactured before 1977. Such 
transformers and capacitors might be found in  
• Old industrial equipment (e.g., welding equipment),  
• Medical equipment (e.g., x-ray machines), and  
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• Household appliances (e.g., refrigerators, 
microwaves and televisions). 
Key Points • The primary route of exposure to PCBs in the 
general population is the consumption of 
contaminated foods, particularly meat, fish, and 
poultry. 
• Occupational exposure to PCBs occurs mainly via 
the inhalation and dermal routes. 
o Although occupational exposure no longer occurs 
as a result of the manufacture of PCB-containing 
products, it might still occur during the 
maintenance or repair of equipment 
manufactured before 1977 that may contain 
PCBs or as a result of accidents involving such 
equipment. 
o Occupational exposure might also occur during 
waste-site cleanup or disposal activities. 
Progress Check 3. Which of the following statements is NOT 
CORRECT? 
A. The primary route of exposure to PCBs in the 
general population is consuming contaminated 
foods. 
B. Over the past two decades, the general overall 
trend is decreasing concentrations of PCBs in 
most environmental media. 
C. Over the past two decades, PCB body burdens in 
humans have shown no changes. 
D. Occupational exposure to PCBs occurs mainly via 
the inhalation and dermal routes. 
To review relevant content, see “Non-occupational 
and Occupational Exposure Routes” in this section. 
Who Is at Risk of Exposure to PCBs? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• Identify who is at risk of exposure to PCBs. 
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Introduction People with potentially high exposures to PCBs include 
• Recreational and subsistence fishers who typically 
consume larger quantities of locally caught fish 
than the general population, 
• Children with in utero and lactational exposure to 
PCBs from mothers who eat large quantities of 
contaminated fish during pregnancy and while 
nursing, 
• Certain farmers and their families who consume 
PCB-contaminated food via their own farm-raised 
beef and dairy cattle, and 
• People living near incinerators, other PCB-disposal 
facilities, or NPL hazardous waste sites where PCBs 
have been detected. 
Although PCBs are no longer manufactured in the United 
States, workplace exposure potentially may exist. In 
occupational settings, persons who repair and maintain 
equipment with capacitors and transformers 





Due to the factors of culture and lifestyles, sport anglers 
and subsistence fishers may consume 10 times more 
fish and seafood than average U.S. consumers. Many of 
these subsistence fishers are American Indian, ethnic 
minority, or immigrant populations.  
The special dietary practices of these populations can 
lead to significant exposures to persistent pollutants 





Children of mothers who eat large quantities of 
contaminated fish may be exposed to PCBs 
prenatally and while breastfeeding. 
Several studies have reported that prenatal exposure to 
PCBs has been confirmed among children of consumers 
of contaminated fish and certain other groups [Fein et 
al. 1984; Jacobson JL et al. 1990b; Jacobson SW et al. 
1985; Swain and Swain 1991]. Other studies have 
indicated that lactating women whose diets are high in 
PCB-contaminated fish potentially can increase the PCB 
exposure for their breastfeeding infants [Dewailly et al. 
1989; Fitzgerald et al. 1998; Greizerstein et al. 1999; 
Rogan et al. 1985]. Fetuses and neonates are more 
sensitive to PCBs than are adults. During these early life 
stages, the hepatic microsomal enzyme systems that 




Farmers and their families who consume PCB-
contaminated food via their own farm-raised beef 
and dairy cattle may be exposed.  
During the 1940s and 1950s, the insides of concrete 
silos on many farms in the Midwest United States were 
coated with sealants containing PCBs. Over time, these 
sealants peeled off and became mixed with silage used 
to feed beef and dairy cattle. Farmers and their families 
who lived on these farms and who regularly ate farm-
raised beef and dairy products were exposed to PCBs. 
Although most of these silos have been dismantled and 
removed, the remaining silos represent a potential 
source of exposure to PCBs [Hansen 1987; Humphrey 






Persons living near incinerators, other PCB-
disposal facilities, or NPL hazardous waste sites 
where PCBs have been detected may be exposed. 
Persons living near incinerators, other PCB-disposal 
facilities, or any of the 500 current or former hazardous 
waste sites on the  NPL sites where PCBs have been 
found may be also at increased risk for exposure to 
PCBs [ATSDR 1987; Hazdat 2000; Hermanson and Hites 
1989; Robertson and Ludewig 2011; Stehr-Green et al. 





PCBs are metabolized mainly in the liver, thus, persons 
with impaired hepatic function might be at increased risk 
because their ability to detoxify and excrete these 
compounds is diminished.  
Persons with incompletely developed glucuronide 
conjugation mechanisms (such as Gilbert syndrome or 
Crigler-Najjar syndrome) have impaired liver function, 
as do persons with chronic liver diseases such as 
cirrhosis or hepatitis B [Calabrese et al. 1977; Lester et 
al. 1964]. 
Similarly, because hepatic function normally declines 
with age, elderly persons may be more susceptible to 
the effects of exposure to PCBs. 
Children’s 
Susceptibility 
Infants and young children consume a greater amount 
of food per kilogram of body weight than do adults.  
Therefore, they have proportionately greater exposure 
to PCBs than do adults eating food with the same level 
of contamination [ATSDR 2000]. In addition, as 
mentioned earlier, fetuses and neonates are potentially 
more sensitive to PCBs than are adults because their 
hepatic microsomal enzyme systems that facilitate the 




PCB levels in blood and body tissues were 10–1,000 
times higher in persons exposed to PCBs in the 
workplace than in non-occupationally exposed persons 
[Kreiss and Kreiss 1985; Wolff 1985; Yakushiji et al. 
1978]. 
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The United States no longer produces PCBs or products 
containing PCBs (e.g., capacitors, transformers, and 
electrical equipment), thus occupational exposure to 
PCBs no longer occurs in those settings. However, 
workers can have inhalation or dermal contact with PCBs 
when repairing or performing routine maintenance on 
older equipment or electrical transformers, and during 
accidents or spills involving PCBs [Fait et al. 1989; 
Schecter AJ and Charles 1991; Welsh 1995; Wolff 
1985]. Exposure can also occur during the disposal of 
materials containing PCBs at hazardous waste sites, 
waste-site cleanup, or demolishing buildings containing 
PCBs [Luotamo et al. 1993; Robertson and Ludewig 
2011]. 
Specific occupations with risk for exposure to PCBs in 
the National Occupational Exposure Survey 
(NOES)[NIOSH 1989] include 
• Construction work, 
• Demolition work, 
• Electric cable repair, 
• Electroplating, 
• Emergency response, 
• Firefighting, 
• Hazardous waste hauling or site operation, 
• Heat exchange equipment repair, 
• Maintenance or cleaning, 
• Medical laboratory technician or technologist, 
• Metal finishing, 
• Non-cellulose fiber industry, 
• Paving and roofing, 
• Pipefitting or plumbing, 
• Semiconductor and related industries, 
• Timber products manufacturing, 
• Transformer or capacitor repair, and 
• Waste-oil processing. 
Key Points • Recreational and subsistence fishers who consume 
large amounts of contaminated fish may be at 
increased risk for high-level exposure to PCBs. 
• Populations with increased exposure to PCBs 
include 
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o Children of mothers who eat large quantities of 
contaminated fish during pregnancy and while 
nursing; 
o Farm families who eat PCB-contaminated food; 
and  
o Persons who live near incinerators, other PCB-
disposal facilities, or NPL hazardous waste sites 
where PCBs have been detected. 
• Persons with compromised hepatic function might 
metabolize PCBs less efficiently than healthy 
persons. 
• Although the United States no longer manufactures 
PCBs, workers can be exposed to PCBs during 
repair of equipment manufactured before 1977, 
accidents or spills involving PCB, and waste-site 
cleanup or disposal activities. 
Progress 
Check 
4. Of the following, who may be at increased risk of 
high-level exposure to PCBs? 
A. Sport anglers and subsistence fishers. 
B. Workers whose jobs include routine maintenance 
of equipment or electrical transformers 
manufactured before 1977. 
C. The children of mothers who eat large quantities 
of contaminated fish during pregnancy and while 
nursing. 
D. All of the above. 
To review relevant content, see all topics in this 
section. 




Upon completion of this section, you will be able to 
• Describe EPA’s maximum contaminant level (MCL) 
for PCBs in drinking water. 
• Describe FDA’s tolerance levels for PCBs in food. 
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Introduction The U.S. government has developed standards and 
regulations for PCBs that are designed to protect the 




The Occupational Safety and Health Administration 
(OSHA)’s permissible exposure limit (PEL) is a time-
weighted average (TWA) airborne concentration of 1.0 
milligrams per cubic meter (mg/m3) for PCBs containing 
42% chlorine (average molecular formula of C12H7Cl3). 
The PEL for PCBs with 54% chlorine and an average 
molecular formula of C12H5Cl5 is 0.5 mg/m3 (OSHA 
1998a). 





• Sprays, and  
• PCB-laden dust particles. 
OSHA recognizes that PCBs can be absorbed through 
intact skin; therefore, both dermal and inhalation 
exposure routes should be evaluated by an industrial 
hygienist. 
The National Institute for Occupational Safety and Health 
(NIOSH)FDA recommends a 10-hour TWA of 1.0 
micrograms per cubic meter (μg/m3) based on the 
minimum reliable detectable concentration and the 
potential carcinogenicity of PCBs [NIOSH 2005]. 
NIOSH also recommends that all workplace exposures be 






EPA considers PCBs a probable human carcinogen and 
prohibits industrial discharges under the Clean Water Act 
Effluent Guidelines. 
EPA’s goal for drinking water’s maximum contaminant 
level is zero, and the enforceable MCL for PCBs in public 
water systems is 0.0005ppm [EPA 2001]. 
EPA requires that PCB spills or accidental releases into 
the environment of 1 pound or more be reported to EPA 
[ATSDR 2000]. 
Food 
FDA mandates tolerances of 0.2–3.0 ppm PCBs for all 
foods, with a tolerance level in fish of 2 ppm. FDA also 
limits PCBs in paper food-packaging materials to 10 ppm 
[FDA 1996c]. 
The Food and Agriculture Organization (FAO) and the 
World Health Organization (WHO) allow a daily PCB 
intake of 6 μg/kg per day [AAP 2003]. 
 Table 1. Standards, regulations, and 
recommendations for PCBs 




for PCBs with 
42% Cl 
0.5 mg/m3 
for PCBs with 
54% Cl 
Enforceable; 










































*TWA (time-weighted average): TWA concentration for 
a normal workday and a 40-hour workweek to which 
nearly all workers may be repeatedly exposed 
†PEL (permissible exposure limit): highest level of PCBs 
in air to which a worker may be exposed, averaged 
over an 8-hour workday 
‡MCL (maximum contaminant level): enforceable level 
for drinking water 
μg/kg: microgram per kilogram 
μg/m3: microgram per cubic meter  
ppm: parts per million 
 
Key Points • OSHA’s PEL is 1,000 μg/m3 for PCB mixtures 42% 
chlorinated and 500 μg/m3 for compounds 54% 
chlorinated. 
• EPA’s enforceable MCL for PCBs in public drinking-
water systems is 0.0005 ppm. 
• FDA’s tolerance levels for PCBs in food range 




5. Which of the following statements is FALSE 
regarding U.S. standards for PCBs levels? 
A. EPA has set an enforceable MCL for PCBs in 
public drinking water systems. 
B. EPA considers PCBs a probable human 
carcinogen and prohibits industrial discharges 
under the Clean Water Act Effluent Guidelines. 
C. FDA has banned PCBs in paper food-packaging 
materials. 
D. NIOSH recommends that all workplace 
exposures to PCBs be reduced to the lowest 
feasible level. 
To review relevant content, see “Environmental 
Standards” in this section. 
What Is the Biologic Fate of PCBs in Humans?  
Learning 
Objective  
Upon completion of this section, you will be able to  
• Describe the characteristics of PCB metabolism in 
humans. 
Introduction  Rates of PCB metabolism vary greatly with the degree of 
chlorination of the biphenyl rings and the positions of 
the chlorines on these rings. 
In the environment, PCBs undergo environmental 
alterations through  
• Partitioning,  
• Chemical transformation, and  
• Preferential bioaccumulation.  
As a result, compositions of environmental PCB mixtures 





Humans can absorb PCBs by the:  
• Inhalation,  
• Oral, and  
• Dermal routes of exposure.  
Although PCBs are readily absorbed into the body, they 
are slowly metabolized and excreted. 
PCBs initially distribute preferentially to the liver and 
muscle tissue. 
PCBs, especially the highly chlorinated congeners, tend 
to accumulate in lipid-rich tissues due to their lipophilic 
nature. Greater relative amounts of PCBs are usually 
found in  
• Adipose tissue,  
• Breast milk,  
• The liver, and  
• Skin [ATSDR 2000; Matthews et al. 1984]. 
Metabolic 
Pathways 
The liver is the primary site of metabolism of PCBs, 
which occurs via hydroxylation and conjugation with 
glucuronic acid and sulfates. 
PCBs are metabolized by the microsomal 
monooxygenase system catalyzed by cytochrome P-450 
to phenols (via arene oxide intermediates), which can be 
conjugated or further hydroxylated to form a catechol 
[Safe SH 2007]. Glucuronide and sulfate conjugates are 
excreted mainly in the urine, whereas hydroxylated 
metabolites are excreted mainly in the bile. 
The rate of individual congener metabolism depends on 
the number and position of chlorine atoms. Steele et al. 
estimated the half-life in humans for lower chlorinated 
biphenyls (Aroclor 1242) as 6–7 months and the 
corresponding half-life for the more highly chlorinated 
biphenyls as 33–34 months [Steele et al. 1986]. Phillips 
et al. measured total PCBs in capacitor workers and 
calculated half lives of 2.6 and 4.6 years for the lower 
(Aroclor 1242) and higher (Aroclor 1254) chlorinated 
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biphenyls, respectively [Phillips et al. 1989]. A more 
recent study, taking into account of high initial body 
burden, ongoing environmental exposure, low serum 
levels, and congeners with very long half-lives, has 
showed the estimated half-lives during a period of high 
internal dose were 1.74 years for Aroclor 1242 and 6.01 
years for Aroclor 1254. Half-lives during a period of low 
internal dose were estimated to be 21.83 years and 
133.33 years for Aroclor 1242 and Aroclor 1254, 
respectively [Hopf et al. 2013]. 
In general, less-chlorinated PCB congeners are more 
readily metabolized than are highly chlorinated 
congeners. As a result of this preferential metabolism, 
highly chlorinated congeners tend to remain in the body 
longer than do less-chlorinated congeners. Highly 
chlorinated congeners therefore tend to become more 
concentrated in adipose tissues, where they are stored 
in solubilized form.  
Excretion PCBs are primarily excreted after they have been 
conjugated and transformed into more polar 
metabolites. The major routes of excretion of PCBs are 





Environmental PCBs occur as mixtures whose 
compositions differ from the commercial mixtures. This 
is because after release into the environment, PCB 
mixture composition changes over time through 
chemical transformation and preferential 
bioaccumulation [Cogliano 1998]. 
Chemical transformation can occur through 
biodegradation of PCB mixtures in the environment. 
PCBs with higher chlorine content are extremely 
resistant to oxidation and hydrolysis. 
Preferential bioaccumulation occurs in living organisms. 
Bioaccumulation through the food chain tends to 
concentrate congeners of higher chlorine content. In 
humans, bioaccumulated PCBs also appear to be more 
persistent in the body [Hovinga et al. 1992]. This is 
significant because bioaccumulated PCBs appear to be 
more toxic than original Aroclors in animals [Aulerich et 
al. 1986; Cogliano 1998]. 
Key Points • PCBs are stored in adipose tissues. 
• The liver is the primary site of metabolism of PCBs. 
• The slow metabolism and high lipid solubility of 
PCBs lead to bioaccumulation. 
• Binding of PCB metabolites to nucleophilic cellular 
macromolecules may contribute to the toxic effects 
of PCBs. 
• After release into the environment, PCBs occur as 
mixtures whose compositions differ from the 
commercial mixtures. Bioaccumulated PCBs also 
appear to be more persistent in the body. 
Progress 
Check 
6. Which of the following statements about the 
biologic fate of PCBs is NOT CORRECT? 
A. The liver is the primary site of PCBs metabolism, 
which occurs via hydroxylation and conjugation 
with glucuronic acid and sulfates. 
B. Less-chlorinated congeners are more readily 
metabolized than are highly chlorinated 
congeners. 
C. Highly chlorinated congeners tend to become 
more concentrated in muscle. 
 39 
D. Bioaccumulated PCBs appear to be more 
persistent in the body. 
To identify relevant content, see all topics in this 
section. 
What Are Adverse Health Effects of PCB Exposure? 
Learning 
Objective 
Upon completion of this section, you will be able to  
• Describe adverse health effects associated with 
exposure to PCBs. 
Introduction 
 
Human exposures to relatively high levels of PCBs have 
occurred primarily in persons working in plants that 
extensively manufactured and used PCBs and PCB-
containing equipment. Occupational exposure to PCBs 
can result in a broad spectrum of effects that includes 
• Increased levels of some liver enzymes, with 
possible hepatic damage, 
• Chloracne and related dermal lesions, and 
• Respiratory problems [Alvares et al. 1977; Chase 
et al. 1982; Emmett and Emmett 1985; Lawton et 
al. 1985; Meigs 1954; Ouw et al. 1976; Safe S 
1993; Warshaw et al. 1979]. 
Potential adverse human health effects of low-level 
environmental exposure to PCBs are complex and still 
need further validation [Safe SH 2007]. 
In animal studies, commercial PCBs elicit a broad range 
of toxic responses including: 
• Acute lethality, 
• Body weight loss, 
• Carcinogenesis, 
• Dermal toxicity, 
• Fatty liver, 
• Genotoxicity, 
• Hepatomegaly, 




• Reproductive and developmental toxicity, 
• Thymic atrophy, and 
• Thyroid hormone-level alterations. 




PCBs are metabolized by the microsomal 
monooxygenase system catalyzed by cytochrome P-450 
to phenols (via arene oxide intermediates), which can 
be conjugated or further hydroxylated to form a 
catechol. Arene oxide intermediates are electrophilic in 
nature. They can covalently bind to nucleophilic cellular 
macromolecules (e.g., protein, DNA, RNA) and induce 
DNA strand breaks and DNA repair, which can 
contribute to the toxic response of PCBs. Additionally, 
arene oxide intermediates can be conjugated with 
glutathione and further metabolized to form 
methylsulfonyl metabolites, which have been identified 
in human serum and tissue samples and in laboratory 
animals. Binding of methylsulfonyl metabolites to some 
proteins may contribute to some of the toxic effects of 
PCBs. It has also been hypothesized that hydroxylated 
PCB metabolites could contribute to the toxicity of PCBs 





Chloracne and related dermal lesions have been 
reported in workers occupationally exposed to PCBs. 
Mild to moderate chloracne was observed in 7 of 14 
workers exposed to 0.1 mg/m³ Aroclors for an average 
duration of 14.3 months [Meigs 1954]. Among 80 
workers who manufactured capacitors in Italy, 10 cases 
of acne or folliculitis, or both, and 5 cases of dermatitis 
were reported. All of the workers with chloracne were 
employed in high exposure jobs. Their blood PCB 
concentrations ranged from 41 to 1319 µg/kg [Maroni et 
al. 1981]. 
In a person with PCB-induced chloracne, the acne-like 
lesions arise as a result of inflammatory responses to 
irritants in the sebaceous glands. Chloracne usually 
begins with the formation of keratin plugs in the 
pilosebaceous orifices. The resulting inflammatory 
folliculitis stimulates keratinization of the sebaceous 
gland ducts and outer root sheath of the hair, leading to 
the formation of keratin cysts.  
The chin, periorbital, and malar areas are most often 
involved, although lesions might also appear in areas 
not usually affected by acne vulgaris (e.g., the chest, 
arms, thighs, genitalia, and buttocks). The most 
distinctive lesions are cystic and measure 1–10 mm, 
although comedonal lesions can also be present. The 
cysts and comedones can become inflamed and 
secondarily infected, and papules and cysts can be 
surrounded by edema and erythema [Crow 1970; Letz 
1983]. 
Chloracne generally indicates systemic toxicity and can 
be caused by not only dermal contact but also ingestion 
of PCBs. However, the absence of chloracne does not 
rule out exposure [Kimbrough 1980; Letz 1983]. No 
reliable dose-response model exists for chloracne in 
exposed populations, and the dose-response 
relationship might be dependent on individual 
predisposition. Chloracne typically develops weeks or 
months after exposure. The lesions are often refractory 
to treatment and can last for years or decades. 
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In addition to chloracne, other dermal effects noted in 
some PCB-exposed workers include pigmentation 
disturbances of skin and nails, erythema and thickening 
of the skin, and burning sensations [Fischbein et al. 
1982; Fischbein et al. 1979; Ouw et al. 1976; Smith et 
al. 1982]. 
Skin effects were reported widely among victims of the 
Yusho (Japan) and Yu-Cheng (Taiwan) poisoning 
episodes in 1968 and in 1978, respectively. In these 
episodes, persons were exposed to PCBs and their heat-
degradation products, mainly polychlorinated 
dibenzofurans (PCDFs). Exposure to PCBs occurred by 
consuming rice oil that had become contaminated by 
heat-degraded PCBs during processing. Unlike usual 
PCB mixtures, the Yusho and Yu-Cheng mixtures were 
heated in thermal heat exchangers during the cooking 
process, resulting in contamination of the oil by 
chlorinated dibenzofurans as well as PCBs. This co-
contamination created controversy [Anonymous 1997; 
Kimbrough et al. 2003; Ross 2004] about the extent to 
which the health effects observed in the Yusho and Yu-
Cheng populations can be attributed to PCBs 
legitimately, as opposed to the dibenzofuran co-
contaminants. 
No adverse dermal effects have been reported in 
persons who consume large amounts of Great Lakes fish 
contaminated with PCBs and other environmentally 
persistent chemicals, or in other cohorts from the 
general population. However, whether this outcome was 
systematically studied in these cohorts is unknown 
[ATSDR 2000]. 
A skin lesion exactly like chloracne in humans has been 
observed in several species of animals experimentally 
exposed to PCBs [Allen 1975]. After monkeys incur 
long-term oral exposure to commercial PCB mixtures, 
related dermal effects are well characterized and 
generally are similar to those observed in humans 
[ATSDR 2000]. 
Key Points • Conclusive evidence that exposure to PCBs induces 
adverse dermal effects in humans exists. 
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Courval, DeHoog et al. [1999] conducted a study of 626 
married couples in Michigan. The relative risk of 
conception failure (defined as inability to conceive after 
12 months) rose in men but not in women with 
increasing consumption of PCB-contaminated fish. Some 
evidence shows that increased intake of PCB-
contaminated fish can shorten menstrual cycle length, 
but no adverse association was found between the 
duration of fish consumption and time-to-pregnancy in 
the same population.   
In a study of 1,820 multigravida women, no significant 
association was found between low-to-moderate PCB 
intake and clinically recognized spontaneous fetal death 
[Mendola et al. 1995]. 
A recent oocupational cohort study examined the data 
from 2595 live births of female workers from three 
capacitor plants and found no evidence of altered sex 
ratio among children born to PCB-exposed female 
workers [Rocheleau et al. 2011]. 
The first epidemiologic investigation to demonstrate an 
association between the amounts of PCB-contaminated 
fish eaten by pregnant women and behavioral deficits in 
their newborns was the Michigan Maternal Infant Cohort 
Study, published in 1984 [Fein et al. 1984; Jacobson 
SW et al. 1985]. In this study, developmental and 
cognitive deficits were observed in the children of 
mothers who had eaten moderate to high amounts of 
contaminated fish during the six years preceding 
pregnancy and who continued to do so during 
pregnancy. Developmental effects in this population 
included statistically significant decreases in  
• Gestational age (4.9 days),  
• Birth weight (160–190 grams), and 
• Head circumference (0.6 centimeters). 
In addition, infants born to mothers who had eaten the 
greatest amount of contaminated fish during pregnancy 
exhibited weaker reflexes, greater motor immaturity, 
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and more pronounced startle responses compared with 
infants born to women who had consumed less fish.  
It is essential that women of childbearing age be aware 
of fish advisories to ensure they not only limit their 
consumption of fish with elevated PCB levels but also 
learn how to prepare fish to limit their PCB ingestion. 
Follow-up studies of the children from this cohort have 
demonstrated that the effects of perinatal exposure to 
PCBs are persistent. At four years of age, these children 
still had deficits in  
• Weight gain,  
• Depressed responsiveness, and  
• Reduced performance on the visual recognition-
memory test.  
At 11 years of age, the children of highly exposed 
mothers were  
• Three times more likely than controls to have low 
full-scale verbal IQ scores, 
• Twice as likely to lag behind at least 2 years in 
reading comprehension, and  
• More likely to have difficulty paying attention 
[Jacobson JL et al. 1990a, 1990b]. 
Recent studies indicate that maternal consumption of 
PCB-contaminated fish can cause disturbances in 
reproductive parameters and neurobehavioral and 
developmental deficits in newborns and older children. 
Prenatal exposure to PCBs from the mother’s body 
burden, rather than exposure through human milk, is 
believed to account for the developmental effects of 
these compounds [Jacobson JL et al. 1996; Longnecker 
et al. 2003; Ribas-Fito et al. 2001; Schantz et al. 2003]. 
Similar reproductive, developmental, and 
neurobehavioral deficits have been reported in children 
born to women who were pregnant during the Yusho 
and Yu-Cheng incidents [Hsu et al. 2003; Hsu et al. 
2005; Yang et al. 2005].  
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Developmental delays were seen at all ages and were 
greater in children who were smaller and had neonatal 
signs of intoxication or nail deformities, or both. Follow-
up testing indicated that effects on cognitive 
development persisted for several years after exposure 
[Guo et al. 1995]. 
In rhesus monkeys, exposure to PCBs is associated with 
alterations in the menstrual cycle, decreases in fertility, 
increases in spontaneous abortion, and a reduced 
number of conceptions [Arnold et al. 1990; Barsotti et 
al. 1976]. 
Key Points • Reproductive function may be disrupted by 
exposure to PCBs. 
• Neurobehavioral and developmental deficits have 




Limited but corroborative occupational data indicate a 
potential for toxic effects in the thyroid system in 
humans. Studies that have examined relationships 
between exposure to PCBs and thyroid hormone status 
have reported a variety of results. Findings include both 
negative and positive significant correlations between 
exposure to PCBs and circulating levels of thyroid-
stimulating hormone (TSH), T4, or T3. These findings 
are dependent on the: 
• Specific type of analysis for exposure to PCBs,  
• Age of the cohort, and  
• Specific exposure scenario [Emmett et al. 1988; 
Koopman-Esseboom et al. 1994; Langer et al. 
1998; Longnecker et al. 2003; Nagayama et al. 
1998; Osius et al. 1999]. 
In a Dutch population, elevated levels of PCBs 
correlated with lower maternal levels of circulating 
triiodothyronine and total thyroxine and with higher 
plasma levels of TSH in infants during the second week 
and third month after birth. Infants exposed to higher 
levels of PCBs also had lower plasma levels of free 
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thyroxine and total thyroxine in the second week after 
birth [Koopman-Esseboom et al. 1994]. 
In addition, a significantly elevated odds ratio for goiter 
was found among the Yu-Cheng cohort [Guo et al. 
1999], suggesting the possibility of excessive thyroid 
disease in a population that experienced relatively high 
exposures to mixtures of PCBs and PCDFs.  
Thyroid hormones are essential for normal behavioral, 
intellectual, and neurologic development. Thus, the 
deficits in learning, memory, and attention processes 
among the offspring of women exposed to PCBs are 
partially or predominantly mediated by alterations in 
hormonal binding to the thyroid hormone receptor 
[ATSDR and EPA 1998]. Some PCB congeners are 
capable of competing with endogenous hormone for 
binding to this receptor, suggesting a possible 
mechanism of thyroid toxicity. Hydroxylated PCB 
metabolites appear to be particularly potent in this 
regard [ATSDR 2000]. 
Studies in animals, including rodents and primates, 
provide evidence of thyroid hormone involvement in 
PCB toxicity. The most convincing evidence that PCBs 
can exert toxicity by disrupting thyroid hormone system 
derives from two studies in rats [Cooke et al. 1996; 
Goldey et al. 1998]. 
The contribution of persistent organic pollutants (POPs) 
exposure to the incidence of diabetes has received little 
attention until recently. Recent studies in populations 
exposed to PCBs and chlorinated pesticides found a 
dose-dependent elevated risk of diabetes [Carpenter 
2008]. 
Key Points • The epidemiological studies suggest a link between 
exposure to PCBs and thyroid hormone toxicity in 
humans. 
• Studies in animals provide evidence of thyroid 
hormone involvement in the mechanism of PCB 
toxicity. 
Hepatic Effects Evidence for liver effects of occupational exposure to 
PCBs is essentially limited to elevation of serum liver 
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 enzymes that are routinely examined in clinical assays. 
These serum liver enzymes include aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), glutamyl transpeptidase (GGT) and other 
biochemical indices (e.g., bilirubin). No overt 
hepatotoxicity has been seen in workers exposed to 
PCBs [ATSDR 2000]. 
A cross-sectional survey found no significant differences 
in liver function test results between workers who 
manufacture capacitors with low-level chronic exposure 
and non-exposed controls [Fischbein et al. 1979]. 
However, in another cross-sectional study, liver function 
tests showed abnormalities that seemed to correlate 
with serum PCB levels [Maroni et al. 1981]. 
Increases in urinary excretion of porphyrins appear to 
be associated with occupational exposure to PCBs, an 
effect that is believed to be secondary to the induction 
of hepatic microsomal enzymes. Total bilirubin levels 
exhibit a positive correlation with serum PCB levels 
[Colombi et al. 1982; Maroni et al. 1984; Smith et al. 
1982]. 
PCBs are more potent enzyme inducers than 
phenobarbital, a drug that occasionally causes clinical 
problems due to its microsomal enzyme-inducing 
effects. The health implications of enzyme induction 
include the occurrence of disease secondary to 
increased metabolism of endogenous or exogenous 
substances and interference in medical therapy due to 
increased metabolism of administered drugs. The 
enzyme-inducing effects of PCBs can persist long after 
cessation of exposure [Letz 1983]. 
In the Yu-Cheng population, the incidence of chronic 
liver disease and cirrhosis was significantly higher than 
the incidence of these conditions in the general 
population of Taiwan. Asymptomatic hepatomegaly has 
been reported in exposed workers, many of whom had 
concomitant elevated serum PCB levels. Due to the 
mixed chemical nature of the exposure, the results 
cannot be attributed solely to PCBs [ATSDR 2000]. 
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Liver damage is a consistent and prominent finding 
among animals exposed to PCBs, particularly rats and 
monkeys, which are the species tested most 
extensively. Liver effects are similar in nature among 
species and appear to be reversible when mild. Liver 
effects characteristically include 
• Fat deposition, 
• Fibrosis, 
• Hepatic microsomal enzyme induction, 
• Increased serum levels of liver-related enzymes 
indicative of possible hepatocellular damages, 
• Liver enlargement, and 
• Necrosis [ATSDR 2000]. 
Key Points • Although liver damage is common in animals 
exposed to PCBs, overt hepatotoxicity is uncommon 
in humans. 
• Exposure to PCBs can increase serum levels of 




Epidemiologic studies have raised concerns about the 
potential carcinogenicity of PCBs. 
A retrospective analysis of a study of two plants that 
manufactured electrical capacitors in the United States 
found a significant increase in the incidence of cancer. 
The primary target tissues for the cancers were  the 
liver, gallbladder, and biliary tract [Brown 1987].  
Likewise, an increased incidence of melanomas 
associated with exposure to PCBs has also been 
observed for workers who manufactured capacitors 
[Bahn et al. 1976; Ruder et al. 2006; Sinks et al. 1992]. 
Sinks et al. [1992] observed the increased risks for 
brain cancer among workers exposed to PCBs in an 
electrical capacitor manufacturing plant in Indiana, and 
this finding has been further confirmed by a recent 
study from Ruder et al. [2006]. 
One study suggests that exposure to electrical insulating 
fluids, for which the main constituent is PCBs, may 
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cause malignant melanoma of the skin [Loomis et al. 
1997]. 
The results of a mortality study of workers employed 
between 1944 and 1977 at an electrical capacitor 
manufacturing plant were recently reported. The report 
pointed out that PCBs alone or in combination with other 
chemicals could be associated with increased risks for  
• Liver or biliary,  
• Stomach, intestinal, and  
• Thyroid cancers [Mallin et al. 2004]. 
A recent analysis of a cohort of 24,865 capacitor-
manufacturing workers exposed to PCBs at three plants 
showed evidence of associations between cumulative 
exposure to PCBs and increased total cancer and 
intestinal cancer mortality among female long-term 
workers and excess myeloma for male long-term 
workers [Ruder et al. 2014].  
In contrast, increased cancer incidence was not 
observed in male workers who manufactured capacitors 
in Sweden exposed to PCBs for an average of 6.5 years 
[Gustavsson et al. 1986]. The results from the Swedish 
study, however, cannot rule out the possibility of a 
carcinogenic risk from PCB exposure because of the 
small size of the cohort and relatively brief follow-up 
period. 
Different mixtures of PCBs had different potencies and, 
thus, different toxicity. As noted previously, PCB 
mixtures found in the environment are different from 
commercial PCB mixtures. EPA agreed that some 
mixtures of PCBs are more likely to cause cancer than 
others, and found that all PCBs mixtures can cause 
cancer [Cogliano 1998; EPA 1996c]. 
In environmental case-control studies that compared 
PCB concentrations in breast tissue in both women with 
(case patients) and without (case controls) breast 
cancer, some studies reported higher levels of total 
PCBs among case patients than control patients [Falck 
et al. 1992; Guttes et al. 1998; Wassermann et al. 
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1976]. Other studies found no elevated PCB levels in 
breast tissue in patients with breast cancer [Aronson et 
al. 2000; Liljegren et al. 1998; Unger et al. 1984]. A 
recent occupational cohort study found no overall 
elevation in breast cancer risk after occupational 
exposure to PCBs [Silver et al. 2009]. 
In persons without known occupational exposure to 
PCBs, elevations of PCB level in the adipose tissue and 
serum have been associated with an increased risk of 
non-Hodgkin lymphoma (NHL) [De Roos et al. 2005; 
Engel et al. 2007; Hardell E et al. 2001; Hardell L et al. 
1996; Rothman et al. 1997]. 
After registering as Yusho victims, 887 male and 874 
female patients were observed for an average 11 years. 
A retrospective study found statistically significant 
increased liver cancer mortality rates among the males 
compared to national  liver cancer mortality rates 
[Kuratsune et al. 1987]. 
A retrospective mortality study of 1940 Yu-Cheng cases 
found no statistically significant increased mortality from 
liver and intrahepatic bile duct cancers [Hsieh et al. 
1996]. 
Before the comprehensive study conducted by Mayes et 
al. [1998], only commercial mixtures 60% chlorinated 
had been tested, and controversy existed about whether 
mixtures with lower chlorine content were carcinogenic. 
The Mayes et al. study [Mayes et al. 1998] supported 
the position that all PCB mixtures can cause cancer. 
Data from animal studies have shown that PCBs cause 
gastrointestinal tract tumors, hepatocarcinomas, 
leukemia, lymphomas, and pituitary tumors [ATSDR 
2000]. 
On the basis of these laboratory data, EPA has 
determined that PCBs are probable human carcinogens 
and has assigned them the cancer weight-of-evidence 
classification B2 [IRIS 2012]. DHHS concluded that 
PCBs are reasonably anticipated to be carcinogenic in 
humans based on sufficient evidence of carcinogenicity 
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in animals [NTP 2011].  
In February 2013, 26 experts from 12 countries met at 
the International Agency for Research on Cancer 
(IARC), Lyon, France, to reassess the carcinogenicity of 
PCBs. The Working Group considered more than 70 
independent epidemiological studies with informative 
data for carcinogenicity of PCBs in human beings. On 
the basis of sufficient evidence of carcinogenicity in 
humans and experimental animals, the IARC classified 
PCBs as carcinogenic to humans (Group 1). The 
classification is based on consistent association between 
exposure to PCBs and increased risk of melanoma in 
humans [IARC 2013]. 
Key Points • On the basis of data from animal studies, DHHS 
and EPA consider PCBs a probable human 
carcinogen. 
• On the basis of sufficient evidence of 
carcinogenicity in humans and experimental 
animals, the IARC classified PCBs as carcinogenic to 
humans (Group 1). 
Other Effects Occupational and epidemiologic studies have suggested 
or demonstrated other adverse health effects from 
exposure to PCBs. These health effects can involve the: 
• Cardiovascular,  
• Gastrointestinal,  
• Immune,  
• Musculoskeletal, and  
• Neurological systems. 
In southwest Quebec, adults who ate fish from PCB-
contaminated waters had  
• Significantly greater motor retardation,  
• Poorer results on certain memory and attention 
tests, and  
• Higher scores on a standardized confusion scale 
than did control adults.  
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These neurological deficits were directly related to the 
frequency of fish consumption [Mergler et al. 1998]. 
Immune system effects reported in PCB-exposed 
populations include alterations in the ratio of helper to 
killer (CD4+/CD8+) T-cells, decreases in IgA and IgM 
antibody levels, decreases in monocyte and granulocyte 
counts, and decreases in natural killer cell count 
[Svensson et al. 1994]. 
In the Yusho and Yu-Cheng populations, the 
immunosuppressive effects of PCB exposure were 
associated with an increased incidence of persistent 
respiratory infection and enhanced responsiveness to 
mitogens [Guo et al. 1995]. 
Appetite loss has been reported in transformer and 
electrical equipment manufacturing workers exposed to 
various PCB-containing mixtures. Other nonspecific 
gastrointestinal symptoms experienced by workers 
exposed to PCBs include nausea, epigastric distress and 
pain, and intolerance to fatty foods [Emmett et al. 
1988; Smith et al. 1982]. 
A recent study has indicated that several PCB 
metabolites induce gene mutations, chromosome 
breaks, chromosome loss and polyploidization in cells in 
culture and even provided the first evidence that a PCB 
congener is mutagenic in vivo [Robertson and Ludewig 
2011]. 
Key Points • Additional adverse effects of PCBs may involve the 
o Cardiovascular,  
o Gastrointestinal, 
o Genetic systems, 
o Immune,  
o Musculoskeletal, and  




7. Adverse dermal effects have been reported in the 
following subjects EXCEPT 
A. Workers occupationally exposed to PCBs. 
B. Those in the general population who consume 
large amounts of fish contaminated with PCBs 
and other environmentally persistent chemicals. 
C. Victims of the Yusho (Japan) and Yu-Cheng 
(Taiwan) poisoning episodes exposed to PCBs 
and their heat-degradation products. 
D. Monkeys after long-term oral exposure to 
commercial mixtures of PCBs. 
To identify relevant content, see “Dermal Effects” 
in this section. 
8. Which of the following statements about the 
potential carcinogenicity of PCBs is considered 
INCORRECT? 
A. Potential human health effects from exposure to 
mixtures of PCBs do not include cancer.   
B. Some mixtures of PCBs are more likely to cause 
cancer than others. 
C. Exposure to PCBs has been associated with 
increased incidence of some cancers. 
D. Data from animal studies have shown clearly 
that PCBs cause different kinds of tumors. 
To identify relevant content, see “Carcinogenic 
Effects” in this section. 
9. Additional adverse effects of PCBs may include 
which of the following? 
A. Liver damage. 
B. Neurobehavioral and developmental deficits. 
C. Thyroid hormone anomalies. 
D. All of the above. 
To identify relevant content, see “Other Effects” in 
this section. 
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Clinical Assessment  
Learning 
Objective  
Upon completion of this section, you will be able to  
• Describe characteristic findings on clinical 
assessment of patients exposed to PCBs, and  
• Describe a rational approach for evaluating a 
patient  with a history of occupational or 
environmental exposure, or both, to PCBs. 
Introduction Patients who have been exposed to PCBs often are 
undergoing clinical assessment long after their last 
exposure occurred (possibly years). The ability to 
extrapolate peak blood levels is problematic in these 
cases.  
PCBs have low acute toxicity but are of public health 
concern because they persist in the environment, 
bioaccumulate in human and animal tissues, and 
potentially can cause chronic or delayed toxicity. 
Documenting an adequate occupational and 
environmental exposure history in addition to a physical 
examination is essential for identifying health effects 
related to PCBs.   
Identifying cases of chloracne may be helpful, but the 





A detailed history will facilitate the diagnosis of chronic 
PCB poisoning. Pertinent information includes 
occupational histories of all household members and 
history of the patient’s sport and subsistence fish 
consumption. Because PCBs are hepatotoxins, history of 
exposure to other potentially hepatotoxic agents, such 
as ethanol intake and medications with known 
hepatotoxicity, should be obtained. 
During the physical examination, physicians should pay 
particular attention to the skin and hepatic systems. 
Encountering a patient with PCB toxicity should trigger 
consideration of whether this is a sentinel event, 
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indicating the possibility of other similarly exposed 






PCBs have very low potential for producing acute toxic 
effects. The only overt sign of exposure to PCBs is 
chloracne, which is a specific skin lesion. Although 
chloracne may resemble typical adolescent acne, it has 
certain distinct features [Crow 1970; Letz 1983].  
• Chloracne’s most distinctive feature is cystic, skin 
colored lesions that measure 1–10 mm. 
• Chloracne’s other prominent feature is comedonal 
lesions. 
The comedones and cysts can become inflamed and 
secondarily infected with large pustules. 
Unlike adolescent acne, chloracne may occur at any age 
and may involve the arms, back, face, legs, neck, and 
trunk. 
Chloracne can be very persistent and refractory to 
treatment. 
Acneiform lesions do not appear in all severely exposed 
patients, so the absence of chloracne does not rule out 
exposure. New cases of chloracne should be reported to 
the local or state health department. 
Other acute effects that may be seen include eye 
irritation, nausea, and vomiting [LaDou 2006]. 
Elevated liver enzymes are the most sensitive indicator 
of exposure to PCBs in animals, and alterations in  
• AST (SGOT),  
• GGT (GGTP),  
• Bilirubin, and  
• Albumin levels have been reported in human 
epidemiologic studies. 
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The absence of alterations in these liver function 
markers does not rule out excessive exposure to PCBs. 
The presence of specific signs, symptoms, or laboratory 
abnormalities, with the possible exception of chloracne, 
is difficult to relate to exposure to PCBs absolutely in 
any given patient. A practical approach for the routine 
work-up of individual patients potentially exposed to 
PCBs  would be to do the following: 
• Take a through occupational and environmental 
exposure history, 
• Examine  the skin, 
• Order baseline liver function tests, and 
• If indicated, perform subsequent testing limited to 
patients with clinical problems or history of 
extensive exposure such as an accidental spill or a 
capacitor rupture that caused heavy skin 
contamination [Letz 1983]. 
This clinical approach may be used for monitoring 
electrical utility workers or other persons with some 
potential for ongoing occupational exposure.  
Serum PCB level is a useful indicator of a patient’s 
exposure. Serum PCB tests are readily available at most 
commercial reference laboratories. However, serum PCB 







Many people who are chronically exposed to PCBs 
exhibit no overt signs or symptoms of toxicity. Among 
persons with hepatic involvement, signs of exposure to 
PCBs can include  
• Abdominal pain,  
• Anorexia,  
• Jaundice,  
• Nausea,  
• Vomiting,  
• Weight loss, and  
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• Uroporphyria. 
Headache, dizziness, and edema have also been 
reported (see earlier section on Adverse Health Effects 
for more detail). 
Differential 
Diagnosis  
Occupational exposure to PCBs may be accompanied by 
exposure to chlorinated dibenzodioxin and dibenzofuran 
contaminants, which are much more toxic than PCBs in 
comparative animal studies. These substances can 
cause chronic fatigue and elevated liver enzymes. 
Mild chloracne should not be confused with other rashes 
(e.g., acne, seborrheic keratitis, keratoma). A skin 




Workers intermittently exposed to PCBs should have a 
baseline skin examination and liver function tests. 
Follow-up examination can be limited to symptomatic 
persons and workers exposed as a consequence of 
accidental contamination. For persons with signs and 
symptoms consistent with high exposures to PCBs (e.g., 
chloracne, elevated AST and ALT), a serum PCB level 
should be obtained to confirm exposure. 
Key Points • Chloracne is the only known overt sign of PCB 
toxicity; however, the absence of chloracne does 
not rule out exposure. 
• Signs of low level, chronic exposure to PCBs are 
generally subtle, if present at all. 
Progress 
Check 
10. Which of the following should be included in the 
clinical evaluation of a patient with a history of 
exposure to PCBs? 
A. A thorough occupational and environmental 
exposure history. 
B. A thorough skin examination. 
C. Liver function tests. 
D. All of the above. 
To review relevant content, see “Patient History 
and Physical Examinations” in this section. 
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11. PCB exposure may manifest clinically as which of 
the following?  
A. Acne vulgaris. 
B. Chloracne. 
C. Parkinsonism. 
D. Acute tubular necrosis. 
To review relevant content, see “Signs and 
Symptoms – Acute Exposure” and “Signs and 
Symptoms – Chronic Exposure” in this section. 
Clinical Assessment - Laboratory Tests 
Learning 
Objective  
Upon completion of this section, you will be able to  
• Describe measurements that can help diagnose 
exposure to PCBs. 
Introduction The lipophilic nature of PCBs causes them to accumulate 
in fat; consequently, analyzing biopsied adipose tissue 
has been used to measure long-term exposure. 
Serum PCB analysis is less invasive than tissue biopsy, 
and it can be performed by most commercial reference 
laboratories. Although such tests are useful for gauging 
exposure, they may not be consistent with adverse 
health effects. 
Select laboratories have the capability to perform PCB 
analyses on human tissue. Testing human tissue for PCB 




PCBs have been detected in the blood, adipose tissue, 
and breast milk of non-occupationally exposed members 
of the general population [CDC 2009; EPA 1986b; 
Greizerstein et al. 1999; Gunderson and Gunderson 
1995; Patterson et al. 2008]. Since the United States 
stopped making PCB compounds, body burdens of PCBs 
in humans have decreased. This decrease is evidenced 
by lower PCB levels reported in human adipose tissue, 
blood serum, and breast milk [Anderson et al. 1998; 
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Fensterheim 1993; Hanrahan et al. 1999; Lunden et al. 
1998; Schade et al. 1998]. 
PCB compounds generally can be found at the parts per 
trillion (ppt) levels in the lipid stores of humans, 
especially persons living in industrialized societies. The 
general population is exposed to PCB compounds 
primarily by ingesting high-fat foods, such as  
• Dairy products,  
• Eggs,  
• Animal fats, and  
• Some fish and wildlife [CDC 2009; Patterson et al. 
2008].  
However, no specified PCB values are deemed normal or 
toxic levels. 
Some researchers believe that PCB levels in the serum 
and tissue provide a reliable measurement of long-term 
exposure. PCB levels in the serum and tissue can be 
measured by many laboratories although analyses 
results may not be consistent with health effects. 
A correlation between increasing levels of serum PCBs 
and dermatologic findings, including chloracne, has not 
been found consistently in human epidemiologic studies. 
However, statistically significant associations between 
dermatologic effects and plasma levels of higher 
chlorinated PCB congeners have been reported 
[Fischbein et al. 1982; Fischbein et al. 1979; Smith et 
al. 1982]. 
Although PCBs accumulate in breast milk, the American 
Association of Pediatrics (AAP) has concluded that the 
risks posed by PCBs in breast milk are outweighed by 
the benefits of breastfeeding in all but the most unusual 
circumstances. Therefore, AAP does not recommend that 
breast milk be tested for PCBs because the test results 
would not likely change the recommendation to breast 
feed. Additionally, AAP recommends consulting local 
health department officials who are aware of the PCB 
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problems in unusual circumstances or where high 




Liver function tests are nonspecific. 
The combination of asymptomatic hepatomegaly and 
mild, nonspecific elevations of hepatic enzymes suggests 
a chronic inflammatory liver process or hepatitis. 
Hepatitis can be  
• Drug-induced,  
• Genetic,  
• Infectious,  
• Toxic,  
• Caused by ethanol ingestion, or  
• Associated with connective tissue disease.  
The major cause of liver disease in the United States is 
ethanol ingestion. Less common causes are 
environmental exposures, resulting in either acute or 
chronic toxic hepatitis.  
Infectious hepatitis includes disease caused by viruses 
such as A, B, C, and other possible agents of non-A, 
non-B hepatitis. Hepatitis can also occur with Epstein-
Barr virus and cytomegalovirus infections. Some 
connective tissue diseases such as lupus erythematosus 
are associated with a specific type of hepatitis. 
Infiltrative diseases such as sarcoidosis or amyloidosis, 
and rare genetic diseases such as Wilson disease, 
primary hemochromatosis, and alpha-1-antitrypsin 
deficiency, must be excluded. 
Normal liver enzyme values do not rule out significant 
PCB exposure; body burden still might be elevated.  
To help arrive at a diagnosis, viral serology and a 
heterophil antibody test should be considered. If the 
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patient has suggestive signs or symptoms, a serum iron 
and total iron binding capacity, serum copper and 
ceruloplasmin, and antinuclear antibodies might help 
with the diagnosis. Assays for suspected hepatotoxins 
might also be useful. If other tests do not provide 
sufficient information, further evaluation might include 
ultrasound and percutaneous liver biopsy. 
Key Points • Serum or adipose tissue PCB levels can indicate 
exposure, but they are difficult to interpret 
clinically.  
• AAP does not recommend testing breast milk for 
PCBs, and encourages breastfeeding in all but the 
most unusual circumstances. 
• Elevated hepatic enzyme levels are of limited value 




12. Which of the following statements is true? 
A. Testing PCB serum level is expensive and not 
readily available, but correlates well with health 
risk. 
B. AAP recommends that breast milk be tested for 
PCBs because human milk contains a steroid 
that inhibits PCB metabolism and excretion. 
C. The toxic serum PCB value is >20 ppb. 
D. None of the above. 
To review relevant content, see “Direct Biologic 
Indicators” in this section. 




Upon completion of this section, you will be able to 
• Describe the principal treatment strategy for 
managing PCB poisoning and  
• Describe the measures for preventing occupational 
and environmental exposure to PCBs. 
Introduction No specific treatment exists for PCB accumulation. 
Patients should avoid further PCB exposure and also 





Treat acute skin and eye PCB exposure immediately by 
flushing with copious amounts of water. However, post-
contamination washing cannot ensure removal of all 
contamination [Wester et al. 1983]. 
Remove contaminated clothing and discard properly. 
Carefully observe patients with inhalation exposure for 
any systemic signs or symptoms of toxicity and 
administer treatment as necessary. No specific 
measures are available to reduce respiratory tract 
absorption. 
In the rare event of ingestion of PCBs, emesis would be 
contraindicated because of the high risk of aspiration. 
The value of administering activated charcoal after 
ingestion is unknown. Unless a patient has an intact or 
protected airway, administering charcoal is 
contraindicated [Alaspaa et al. 2005; Chyka et al. 
2005]. 
Exposed persons should have periodic follow-up 
examinations with particular attention to hepatic 
function and dermal lesions.  
Key Points • No antidote exists for PCB exposure; therefore, 




No specific treatment is available for chronic PCB 
toxicity. Because no known methods exist for reducing 
the reserves of PCBs in adipose tissues, purging the 
body of PCBs should not be attempted.  
Initial treatment of chloracne is based on  
• Cessation of PCB exposure,  
• Good skin hygiene, and  
• Dermatologic measures commonly used for acne 
vulgaris.  
Given the difficulty in treating chloracne, the patient 
should be referred to a dermatologist. 
If chronic exposure has occurred due to consuming 
contaminated fish or game, the patient should be 
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informed that PCBs tend to accumulate in the body with 
continued exposure, and counseled about the 
importance of minimizing further exposure. 
In areas with a known PCB problem, state and local 
public health or natural resources departments typically 
issue advisories. These advisories specify the waters or 
hunting areas where PCB-contaminated fish and game 
likely are, and list the species and size of fish or game 
that are of concern. Such advisories might completely 
ban consumption, or might recommend limits on the 
frequency with which certain species are to be 
consumed. To minimize the risk for further exposure, 
sport and subsistence fishers are encouraged to 
familiarize themselves with and observe advisory 
recommendations [ATSDR 2000]. 
Patients should be monitored for increased hepatic 
enzymes. Because PCBs are hepatotoxins, history of 
exposure to other potentially hepatotoxic agents should 
be obtained. To minimize the risk of hepatic damage, 
patients should be encouraged to avoid exposure to 
other hepatotoxins, including medications with known 
hepatotoxicity, ethanol, and chlorinated solvents.  
The carcinogenic potential and other risks from exposure 
to PCBs should be carefully reviewed with the patient. 
AAP encourages breastfeeding in all but the most 




















The following measures [LaDou 2006] may be adopted 
at work to avoid exposure to PCBs. 
• Eliminate PCBs from the workplace or implement 
engineering changes to isolate the PCBs. If neither 
of these approaches is feasible, then use special 
PCB-resistant gloves and protective clothing. 
• Maintain adequate ventilation during spill cleanup 
or maintenance of vessels containing PCBs. If this 
is not possible, provide approved respirators. 
• Make provisions for proper decontamination or 
disposal of contaminated clothing or equipment. 
• Post clearly the locations where PCBs are stored as 
required by law. 
• Conduct environmental sampling as necessary to 
ensure adequate worker protection or safety for 
public reentry to contaminated areas. 
• Establish reentry or cleanup levels for dioxins and 
PCBs to protect workers who reoccupy buildings 
after a PCB fire. 
• Record health complaints of any type. 
Medical Surveillance 
Workers intermittently exposed to PCBs should have a 
baseline skin examination and liver function tests. For 
workers with signs and symptoms consistent with large 
exposures to PCBs (e.g., chloracne, elevated AST and 
ALT), obtain confirmation of exposure to determine 




• Open all windows and use fans in your workspace 
when maintaining or repairing any products 
containing PCBs.  
• Wear a respirator or protective gloves, or both. 
• You and your children may be exposed to PCBs by 
eating fish or wildlife caught from contaminated 
locations. Certain states, Native American tribes, 
and U.S. territories have issued advisories to warn 
people about PCB-contaminated fish and fish-eating 
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wildlife. You can reduce your family’s exposure to 
PCBs by following these advisories. 
Key Points • The goal of treating chronically exposed patients is 
preventing any additional exposure to PCBs. 
• Exposure to PCBs at work or home is avoidable if 
the proper preventive measures are adopted. 
Progress 
Check 
13. Which of the following statements regarding 
treatment for chronic PCB toxicity is NOT 
CORRECT? 
A. The goal in treating chronically exposed patients 
is preventing any additional exposure to PCBs. 
B. No specific treatment is available for chronic 
PCB toxicity. 
C. Breastfeeding should be avoided. 
D. No known methods exist for reducing the 
burdens of PCBs in human tissues. 
To review relevant content, see “Chronic Exposure” 
in this section. 
14.  All of the following preventive measures to avoid 
PCB exposure at work or home are true EXCEPT 
A. Use special PCB-resistant gloves and protective 
clothing. 
B. Maintain adequate ventilation during spill 
cleanup or maintenance of vessels containing 
PCBs. If this is not possible, provide masks. 
C. Certain states, Native American tribes, and U.S. 
territories have issued advisories to warn people 
about PCB-contaminated fish and fish-eating 
wildlife. You can reduce your family’s exposure 
to PCBs by obeying these advisories. 
D. Locations where PCBs are stored should be 
clearly posted as required by law. 
To review relevant content, see “Prevention at 
Home” and “Prevention in the Workplace”  in this 
section. 
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What Instructions Should Be Given to Patients 
Exposed to PCBs? 
Learning 
Objective 
Upon completion of this section, you will be able to  
• Describe appropriate instructions for patients exposed 
to PCBs. 
Introduction All patients exposed to PCBs need basic guidance on 
• Self-care, so they can minimize further risks and 
avoid complications to the extent possible, and 
• Clinical follow-up, so they understand when and why 
to return for further medical attention. 
ATSDR has developed a patient education sheet on PCBs 






Patients should be advised to avoid exposures and 
conditions that might further increase their risk of disease 
or worsen their existing condition. 
At Work 
• Eliminate PCBs from the workplace, or implement 
engineering changes to isolate the PCBs. If neither of 
these approaches is feasible, use special PCB-
resistant gloves and protective clothing. 
• Maintain adequate ventilation during spill cleanup or 
maintenance of vessels containing PCBs. If this is not 
possible, provide approved respirators. 
• Make provisions for proper decontamination or 
disposal of contaminated clothing or equipment. 
• Dispose of existing PCBs through appropriate toxic 
waste facilities. 
• Conduct environmental sampling as necessary to 
ensure adequate worker protection or safety for 
public reentry to contaminated areas. 
• Establish reentry or cleanup levels for dioxins and 
PCBs to protect workers who reoccupy buildings after 
a PCB fire. 
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• Report persistent health effects (e.g., unexplained 
weight loss, muscle pain, frequent coughing, and 
sleep problems). These symptoms may be due to 
stress or recall bias and may not be specifically linked 
to the toxic effects of PCBs. 
At Home 
• Open all windows and use fans in your workspace 
when conducting maintenance or repairing any 
products containing PCBs.  
• If ventilation is poor, wear a respirator and protective 
gloves. 
• Seek medical attention immediately if an acute 
exposure occurs. 
• Lower exposure to PCBs by looking for and following 
health advisories issued by states, Native American 
tribes, or U.S. territories when eating fish or wildlife 





PCBs have been implicated as a potential cause of cancer 
in humans. Screening tests are available for breast cancer 
and melanoma. If patients believe that they are being 
exposed to PCBs, advise them how to stop the exposure. 
Also tell them how to contact worksite or environmental 
regulatory agencies that will assess exposure risks and 
prescribe protective actions.  
Advise patients with suspected or confirmed historic 
exposure to PCBs to be seen by you or their primary care 
provider periodically and monitored for signs of disease 
and changes in health status. 
Advise patients to consult their physicians if they develop 
signs or symptoms of PCB exposure such as 
• Appetite loss, 
• Joint pain, 
• Nausea, 
• Skin disorders, changes, or discoloration, 
• Breast changes or lumps, and/or 
• Stomach distress and pain. 
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ATSDR’s patient education sheet on PCBs includes a more 
detailed checklist that you can use to indicate which types 
of follow up are relevant for a given patient. 
Key Points • Advise patients to avoid PCB exposures and 
conditions that might further increase their risk of 
disease or worsen their existing condition. 
• Advise patients to contact their physicians if they 
develop skin problems or other health changes. 
Progress 
Check 
15. Patients who have been exposed to PCBs should be 
advised to 
A. Speak to their employers about reducing 
workplace exposures (if exposures are 
occupational). 
B. Learn how to avoid further exposure. 
C. Know when to call their doctors. 
D. All of the above. 
To review relevant content, see all topics in this 
section. 





Please refer to the following resources for more 
information on the adverse effects of PCBs, the 
treatment of PCB-associated diseases, and 
management of persons exposed to PCBs. 
• ATSDR http://www.atsdr.cdc.gov  
o For chemical emergency situations, contact 
 CDC Emergency Response at 770-488-7100 
and request the ATSDR Duty Officer 
o For chemical non-emergency situations, contact 
 CDC-INFO at http://www.cdc.gov/cdc-info/  
 800-CDC-INFO at (800-232-4636) TTY 888-
232-6348 - 24 Hours/Day 
 E-mail at: cdcinfo@cdc.gov 
 70 
PLEASE NOTE 
ATSDR cannot respond to public inquiry and 
questions about individual medical cases, 
provide second opinions, or make specific 
recommendations regarding therapy. Such 
guidance requires clinical examination by a 
health care provider. 
o Toxicological Profile for Polychlorinated 
Biphenyls 
(PCBs)  http://www.atsdr.cdc.gov/toxprofiles/tp
.asp?id=142&tid=26   
o Addendum to the Toxicological Profile for 
Polychlorinated Biphenyls 
(PCBs)  http://www.atsdr.cdc.gov/toxprofiles/p
cbs_addendum.pdf    
o TOXFAQs for Polychlorinated Biphenyls (PCBs) 
(English)  http://www.atsdr.cdc.gov/toxfaqs/tf.
asp?id=140&tid=26    
o TOXFAQs for Polychlorinated Biphenyls (PCBs) 
(Spanish) http://www.atsdr.cdc.gov/es/toxfaqs/
es_tfacts17.html  
o ATSDR Minimal Response 
Levels http://www.atsdr.cdc.gov/mrls/index.ht
ml  
• Centers for Disease Control and 
Prevention http://www.cdc.gov 
• EPA Polychlorinated Biphenyls 






Please refer to the following Web resources for general 
information on environmental health. 
• ATSDR http://www.atsdr.cdc.gov   
o Taking an Exposure History 
CSEM http://www.atsdr.cdc.gov/csem/csem.as
p?csem=33&po=0   




o Exposure History 
Worksheet http://www.atsdr.cdc.gov/csem/exp
history/docs/CSEMExposHist-26-29.pdf    
o ATSDR Regional Operations. 
 ATSDR regional staff are able to maintain 
current and historic knowledge of the sites 
and issues in their regions through the 
working relationships they have established 
with EPA, other federal and state agencies, 
individual citizens, and community groups. 
 A list of ATSDR's regional staff, the states 
and territories that they cover, and contact 
information can be found 
at http://www.atsdr.cdc.gov/DRO/dro_conta
ct.html  
o ATSDR State Cooperative Agreement 
Program http://www.atsdr.cdc.gov/states/index
.html  
 The Cooperative Agreement Program 
provides essential support to communities 
nationwide to fulfill the mission of ATSDR.  
 The program funds ~30 states and one tribal 
government to help develop and strengthen 
their abilities to evaluate and respond to 
environmental public health issues. 
• CDC http://www.cdc.gov  
o CDC works to protect public health and safety  
by providing information to enhance health 
decisions, and promotes health through 
partnerships with state health departments and 
other organizations.  
o CDC focuses national attention on developing 
and applying activities surrounding disease 
prevention and control (especially infectious 
diseases), environmental health, occupational 
safety and health, health promotion, and  
education designed to improve the health of the 
people of the United States. 
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• National Center for Environmental Health 
(NCEH) http://www.cdc.gov/nceh   
o NCEH works to prevent illness, disability, and 
death caused by interactions between people 
and the environment. NCEH is especially 
committed to safeguarding the health of 
populations that are particularly vulnerable to 
certain environmental hazards—children, the 
elderly, and people with disabilities. 
o NCEH seeks to achieve its mission through 
science, service, and leadership. 
• National Institute of Health 
(NIH) http://www.nih.gov  
o A part of the U.S. Department of Health and 
Human Services, NIH is the primary federal 
agency for conducting and supporting medical 
research. 
• National Institute for Occupational Safety and 
Health (NIOSH) http://www.cdc.gov/niosh/   
o NIOSH is part of the U.S. Department of Health 
and Human Services and is an agency 
established to help ensure safe and healthful 
working conditions for working men and women 
by providing research, information, education, 
and training in the field of occupational safety 
and health. 
• American College of Occupational and 
Environmental Medicine 
(ACOEM) http://www.acoem.org/  
o ACOEM is the nation's largest medical society 
dedicated to promoting the health of workers 
through preventive medicine, clinical care, 
research, and education. 
o ACOEM members are a dynamic group of 
physicians including specialists in a variety of 
medical practices. ACOEM is united to develop 
positions and policies on vital issues relevant to 
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preventive medicine both within and outside of 
the workplace. 
• American College of Medical Toxicologists 
(ACMT) http://www.acmt.net  
o ACMT is a professional, nonprofit association of 
physicians with recognized expertise in medical 
toxicology.  
o ACMT is dedicated to advancing the science and 
practice of medical toxicology through a variety 
of activities. 
• American College of Preventive Medicine 
(ACPM) http://www.acpm.org  
o ACPM is the national professional society for 
physicians committed to disease prevention and 
health promotion.  
o ACPM's 2,000 members are engaged in 
preventive medicine practice, teaching, and 
research.  
• Association of Occupational and Environmental 
Clinics (AOEC) http://aoec.org  
o AOEC is a network of more than 60 clinics and 
more than 250 individuals committed to 
improving the practice of occupational and 
environmental medicine through information 
sharing and collaborative research. 
• Pediatric Environmental Health Specialty Units 
(PEHSUs) http://www.pehsu.net  
o The PEHSUs are developed to provide education 
and consultation for health professionals, public 
health professionals and others about the topic 
of children's environmental health.  
o The PEHSU staff is available for consultation 
about potential pediatric environmental health 
concerns affecting both the child and the family. 
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Health care professionals may contact their 
regional PEHSU site for clinical advice.  
• Poison Control Center 
o The American Association of Poison Control 
Centers (AAPC) may be contacted for questions 
about poisons and poisonings. Their Web site 
provides information about poison centers and 
poison prevention. AAPC does not provide 
information about treatment or diagnosis of 
poisoning, or research information for student 
papers. 
o American Association of Poison Control Centers 
may be contacted at 1-800-222-1222 
or http://www.aapcc.org  
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